Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Myleran, Busulfex
Busulfan is an alkylating antineoplastic agent used to treat chronic myelogenous leukemia (CML) and as a conditioning agent prior to hematopoietic stem cell transplantation (HSCT). It belongs to the class of alkylating agents, specifically the methanesulfonate esters. Busulfan works by cross-linking DNA strands, which prevents cell division and leads to cell death. It is primarily used in combination with other chemotherapy drugs or prior to HSCT.
Used to treat chronic myelogenous leukemia and as a conditioning agent prior to hematopoietic stem cell transplantation.
Busulfan can cause severe bone marrow suppression, pulmonary toxicity (including interstitial lung disease and pulmonary fibrosis), veno-occlusive disease, seizures, and hepatic toxicity. It is also a teratogen and can cause sterility.
Outcome:
Reduced busulfan levels
Mechanism:
Enzyme induction
Outcome:
Potential for hepatotoxicity
Mechanism:
Additive toxicity
Outcome:
Potential for altered drug metabolism
Mechanism:
Competition for metabolic pathways
Most likely new formulation: intravenous formulation with improved bioavailability (2025, 30% confidence)
Based on current usage trends and emerging therapies, there is a low (5%) likelihood of busulfan being withdrawn from the market in the next 5 years.
Alkylating agent, Methanesulfonate ester
Methanesulfonate ester